Celldex Therapeutics CLDX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's operating lease liabilities (current)?
- Celldex Therapeutics (CLDX) reported operating lease liabilities (current) of $1.47M in Q1 2026.
- How has Celldex Therapeutics's operating lease liabilities (current) changed year-over-year?
- Celldex Therapeutics's operating lease liabilities (current) decreased by 2.3% year-over-year, from $1.5M to $1.47M.
- What is the long-term trend for Celldex Therapeutics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Celldex Therapeutics's operating lease liabilities (current) has grown at a 3.2% compound annual growth rate (CAGR), from $1.33M to $1.55M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.